Related Experiment Videos
Effect of sucralfate on phenytoin bioavailability
Drug Intelligence & Clinical Pharmacy
|July 1, 1986
Summary
Sucralfate, an antiulcer medication, may reduce the absorption of phenytoin, an anti-seizure drug. This drug interaction could impact treatment effectiveness, warranting further investigation into its clinical significance.
Area of Science:
- Pharmacology
- Drug Interactions
- Gastroenterology
Background:
- Sucralfate is an antiulcer agent known to bind to various substances in the gastrointestinal tract.
- Its potential to inhibit the oral absorption of co-administered drugs is not extensively studied.
- Understanding drug interactions is crucial for patient safety and therapeutic efficacy.
Purpose of the Study:
- To investigate the effect of sucralfate on the oral bioavailability of phenytoin.
- To determine if sucralfate alters phenytoin absorption and potentially its therapeutic levels.
Main Methods:
- A pharmacokinetic study involving nine healthy subjects.
- Single oral dose of phenytoin (500 mg) administered alone and concurrently with sucralfate.
- Serum phenytoin concentrations monitored over 120 hours.
- Area Under the Curve (AUC48 and AUC120) compared between the two conditions.
Main Results:
- Phenytoin AUC48 was significantly reduced (p < 0.02) when co-administered with sucralfate.
- Phenytoin AUC120 also showed a significant reduction (p < 0.05) with sucralfate.
- While changes in AUC might reflect absorption rate, the results suggest sucralfate impacts phenytoin absorption.
Conclusions:
- Sucralfate appears to affect the oral absorption of phenytoin.
- The clinical significance of this interaction requires further research.
- Caution may be advised when co-administering sucralfate and phenytoin, pending further studies.